ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $76,809,898 | +59.0% | 6,708,288 | 0.0% | 25.63% | +46.4% |
Q3 2022 | $48,300,000 | +20.5% | 6,708,288 | +42.5% | 17.51% | +15.3% |
Q2 2022 | $40,068,000 | -5.1% | 4,708,288 | 0.0% | 15.19% | +17.4% |
Q1 2022 | $42,233,000 | – | 4,708,288 | – | 12.94% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |